Genetic Causes of Cerebral Palsy
5 sections · 20 min
Redefining Cerebral Palsy: Beyond Perinatal Injury
Cerebral palsy (CP) is clinically defined as a group of permanent disorders of movement and posture caused by non-progressive disturbances that occurred in the developing fetal or infant brain. Historically, CP was considered synonymous with perinatal hypoxic-ischemic injury. However, large epidemiological and genomic studies now demonstrate that genetic causes — including chromosomal abnormalities, pathogenic copy number variants, and single-gene disorders — account for approximately 20–30% of CP cases, and potentially more in cases without a clear perinatal etiology.
CP Motor Subtypes
| Subtype | Motor Topography | Predominant Tone | MRI Correlates |
|---|---|---|---|
| Spastic (~80%) | Diplegia / hemiplegia / quadriplegia | Velocity-dependent ↑ tone | PVL (preterm diplegia); MCA infarct (hemiplegia); diffuse injury (quad) |
| Dyskinetic (~15%) | Trunk / limb / whole-body | Dystonia ± choreoathetosis | Bilateral BG/thalamic signal (term HIE); kernicterus → GP |
| Ataxic (~5%) | Trunk / appendicular | Cerebellar ataxia / hypotonia | Cerebellar hypoplasia; posterior fossa malformation |
| Mixed | Variable | Spasticity + dystonia most common | Reflects mixed mechanisms |
GMFCS Levels I–V
| Level | Functional Description | Mobility |
|---|---|---|
| I | Walks without limitations | Community ambulation; runs/jumps with speed & coordination limitations |
| II | Walks with limitations | Assistive device outdoors; limited stairs & uneven surfaces |
| III | Walks with hand-held device | Wheelchair for distances; some household ambulation |
| IV | Wheelchair-dependent | May achieve standing transfers; limited self-mobility |
| V | Transported in wheelchair | No independent mobility; head/trunk control limited |
Clinical Pearl: GMFCS level is the strongest predictor of long-term ambulation. Genetic diagnosis does not change GMFCS but may redirect treatment strategy (e.g., DRD → levodopa instead of SDR).
Key Points
- Modern definition: CP is a clinical syndrome (motor impairment + non-progressive brain abnormality) — not a specific diagnosis; etiology must be sought
- Genetic contribution: ~14–31% of 'idiopathic' CP cases have identifiable genetic cause by chromosomal microarray + exome sequencing; genetic cause more common in term births without perinatal risk factors
- CP mimics (treatable conditions misdiagnosed as CP): dopa-responsive dystonia (DYT-GCH1; see [[dystonia|Genetic Dystonias]] module), GLUT1 deficiency, AADC deficiency (DDC), glutaric aciduria type 1, biotinidase deficiency, arginase deficiency (ARG1) — critical to exclude before accepting CP label
- Brain imaging in CP: MRI normal in 15–30% — higher genetic yield in these cases; periventricular leukomalacia (preterm injury), cortical dysplasia (genetic), vascular patterns (coagulopathy, COL4A1) all provide diagnostic clues
- Clinical subtypes and genetic associations: spastic diplegia (periventricular leukomalacia most common — but also SPAST, PLP1 spastic paraplegia), dystonic CP (often treatable, DRD must be excluded), hemiplegic CP (focal cortical malformation, stroke, COL4A1)
✦ Check Your Understanding
A 4-year-old child born at term without perinatal complications has been labeled with 'spastic diplegic cerebral palsy.' MRI is reported as normal. She has diurnal fluctuation of her tone — worse in the evening, better in the morning. The most important next step is:
Select an answer to reveal the explanation
Chromosomal Abnormalities and CNVs in CP
Chromosomal abnormalities and copy number variants (CNVs) are identified in 8–15% of children with CP phenotype. These include classic chromosomal aneuploidies, sub-microscopic deletions and duplications detected by microarray, and uniparental disomy. Recognition of a chromosomal etiology reframes the diagnosis, provides recurrence risk information, and may identify additional health surveillance needs.
Key Points
- Chromosomal microarray diagnostic yield in CP: ~7–11% when applied to children with CP phenotype regardless of MRI findings; highest yield in term-born children with no perinatal risk factor and normal/non-diagnostic MRI
- 17p13.3 deletions (LIS1/PAFAH1B1, YWHAE): Miller-Dieker syndrome — pachygyria/lissencephaly on MRI; most severe neurological impairment; facial features
- 15q11-13 duplication/Prader-Willi/Angelman: Angelman syndrome can present as 'CP-like' with ataxic gait, absent speech, seizures — SNRPN methylation testing is important
- 1p36 deletion syndrome: hypotonia, moderate-severe intellectual disability, seizures, cardiomyopathy — can present as CP phenotype; specific distinctive features
- Xq28 MECP2 duplication: males with progressive spastic quadriplegia, severe intellectual disability, respiratory infections — clinically resembles CP; distinguished by progressive course and X-linked family history. Somatic mosaicism can also complicate CP phenotype interpretation (see the [[mosaicism|Mosaicism]] module)
✦ Check Your Understanding
A term-born child with moderate intellectual disability, absent speech, seizures, and a happy, social demeanor is initially labeled with CP. SNRPN methylation testing shows only the unmethylated (paternal) band present, with the methylated (maternal) band absent. This child most likely has:
Select an answer to reveal the explanation
Monogenic Causes and CP Mimics
Single-gene variants can produce phenotypes that meet clinical criteria for CP — motor impairment present from infancy in the context of an apparently non-progressive course. At least 10 monogenic conditions are commonly misdiagnosed as CP: DRD (GCH1), HSP (SPG4+), AHC (ATP1A3), leukodystrophies, Rett (MECP2), ARG1 deficiency, GA1 (GCDH), NPC, mitochondrial disease, and spinal cord pathology. A levodopa trial is MANDATORY in any child with dystonia and a normal MRI — DRD response is dramatic within days, low risk, and potentially life-changing. ARG1 deficiency presents as progressive spastic diplegia with elevated plasma arginine and is a treatable urea cycle disorder. Progressive or regressive course rules out CP by definition and demands urgent metabolic and genomic workup.
CP Mimickers — 10 Conditions to Know
| Disorder | Red Flag | Gene | Key Test |
|---|---|---|---|
| Dopa-responsive dystonia | Diurnal variation — worse PM, better AM | GCH1 | Levodopa trial (MANDATORY) |
| Hereditary spastic paraplegia | Progressive spastic diplegia; multi-generational “CP” | SPG4 + >80 genes | Gene panel / WES |
| Alternating hemiplegia of childhood | Episodic hemiplegia alternating sides; onset <18 mo | ATP1A3 | Gene sequencing |
| Leukodystrophies | Regression after plateau | Multiple | MRI white matter signal + WES |
| Rett syndrome | Regression 12–18 mo; hand stereotypies | MECP2 | MECP2 sequencing |
| Arginase deficiency | Progressive spastic diplegia; ID | ARG1 | Plasma arginine |
| Glutaric aciduria type 1 | Macrocephaly + striatal injury after crisis | GCDH | Urine organic acids; newborn screen |
| Niemann-Pick C | VSGP + ataxia + cognitive decline + HSM | NPC1/NPC2 | Oxysterols; filipin staining |
| Mitochondrial disease | Episodic decompensation; multi-system | Multiple | Lactate; Leigh pattern MRI |
| Spinal cord pathology | Progressive diplegia; bowel/bladder dysfunction | N/A | Spinal MRI |
Red Flag Rule: If “CP” is progressive or regressive — STOP. It is not CP. Rethink the diagnosis with metabolic screen + WES/WGS.
Key Points
- DRD (GCH1): diurnal variation of dystonia (worse PM, better AM); normal MRI; levodopa trial MANDATORY — start 1-2 mg/kg/day TID, titrate over 2-4 weeks; dramatic response confirms diagnosis; low risk, potentially life-changing
- HSP (SPG4 and >80 genes): progressive spastic diplegia mimicking CP; thin corpus callosum; AD inheritance — multi-generational 'CP' families are HSP until proven otherwise
- AHC (ATP1A3): episodic hemiplegia alternating sides, onset <18 months; sleep resolves episodes; may develop fixed dystonia over time
- ARG1 (arginase deficiency): progressive spastic diplegia with elevated plasma arginine — treatable UCD with protein restriction; hyperammonemia may be absent or subtle; must check plasma amino acids in any 'progressive CP'
- GA1 (GCDH): macrocephaly + bilateral striatal injury after metabolic crisis; frontotemporal hypoplasia on MRI; identifiable on newborn screen; dietary lysine restriction prevents striatal crisis
✦ Check Your Understanding
A 3-year-old with macrocephaly and a prior diagnosis of 'cerebral palsy' developed acute bilateral striatal injury during a febrile illness. Urine organic acids confirm glutaric aciduria type 1 (GA1). What is the primary mechanism of neurological injury in this disorder?
Select an answer to reveal the explanation
Genetic Workup for Cerebral Palsy
The genetic investigation of CP has evolved from a karyotype-and-wait approach to a comprehensive tiered evaluation combining brain MRI, metabolic screening, chromosomal microarray, and exome sequencing. The yield of genetic testing is highest in term-born children without clear perinatal hypoxic-ischemic injury, children with normal or non-lesional MRI, and children with additional features (distinctive features, family history, regression, movement disorder beyond motor impairment).
Etiological Workup by Scenario
| Scenario | First-line Testing | Key Action |
|---|---|---|
| 1. All CP | Brain MRI | Identifies cause in ~80%. Normal MRI = RED FLAG — pursue genetic/metabolic workup |
| 2. Normal MRI / Unexplained | CMA + epilepsy panel or WES + metabolic screen | PAA, UOA, lactate, acylcarnitines |
| 3. Dyskinetic / Dystonic + Normal MRI | Levodopa trial + CSF neurotransmitters | GCH1/TH genes + plasma arginine |
| 4. Family Hx / Consanguinity / Distinctive Features | CMA → WES/WGS | Trio preferred for de novo detection |
| 5. Progressive / Regression | Metabolic screen + WES/WGS urgently | STOP — reconsider CP diagnosis |
Emerging: WGS as first-tier in some centers — detects SVs, repeat expansions, deep intronic variants; yield ~35–40%.
Key Points
- Tier 1: Brain MRI (3T if possible, with DWI and T2/FLAIR); evaluate for lesion pattern (PVL, cortical malformation, vascular, normal); metabolic panel (plasma amino acids, urine organic acids, lactate, ammonia, acylcarnitines); SNRPN methylation if Angelman features; levodopa trial if any diurnal fluctuation or dystonia
- Tier 2: Chromosomal microarray (SNP-based, for CNV and UPD); Fragile X if appropriate; specific targeted testing based on metabolic/clinical findings (e.g., GLUT1 if CSF:blood glucose low, SLC6A3 if parkinsonism-dystonia)
- Tier 3: Exome sequencing (trio analysis — patient + both parents preferred for de novo detection); highest yield ~25–30% in carefully selected patients with 'idiopathic CP'
- Features predicting high genetic yield: term birth, no HIE, normal MRI OR cortical malformation, family history of developmental delay/CP, additional features beyond motor (epilepsy, regression, movement disorder, distinctive features)
- Whole-genome sequencing: emerging as first-tier in some centers; detects SVs and deep intronic variants missed by exome; may screen for some short tandem repeat disorders; diagnostic yield ~35–40% in selected pediatric neurogenetics populations
✦ Check Your Understanding
Which clinical feature would most strongly support pursuing exome sequencing in a child labeled with CP?
Select an answer to reveal the explanation
Counseling and Management After Genetic Diagnosis
Identifying a genetic etiology in a child labeled with CP changes the clinical trajectory — it provides a precise diagnosis, informs recurrence risk, directs comorbidity surveillance, and increasingly identifies patients eligible for targeted therapies. A genetic diagnosis explains the cause without diminishing access to rehabilitation and therapeutic supports. Treatment approaches (baclofen, trihexyphenidyl, BoNT-A, ITB pump, SDR) are covered in detail in the Genetic Dystonias module.
Key Points
- Recurrence risk depends entirely on the genetic mechanism: de novo CNV or variant — <1% recurrence (germline mosaicism caveat); autosomal recessive — 25% per pregnancy; autosomal dominant variant inherited from affected parent — 50%; X-linked — depends on sex and carrier status
- Identifying treatable causes changes prognosis: DRD responds dramatically to levodopa; GLUT1 improves on ketogenic diet; AADC deficiency responds to gene therapy; GA1 can be prevented with dietary lysine restriction; biotinidase deficiency resolves with biotin
- Comorbidity surveillance by diagnosis: Down syndrome (thyroid, cardiac, sleep apnea); Angelman syndrome (epilepsy, scoliosis); MECP2 duplication (pulmonary hypertension, respiratory failure); SPG4 (urological symptoms, progressive course requiring active physiotherapy)
- The CP label does not preclude genetic investigation: some clinicians are reluctant to pursue genetics after CP diagnosis, believing etiology is established; evidence shows 20–30% of labeled CP cases have genetic causes that matter for management and family planning
- Variant of uncertain significance (VUS) counseling: ~20–30% of exome results yield VUS; distinguish VUS from pathogenic; review annually as databases grow; encourage research participation for data sharing
✦ Check Your Understanding
After exome sequencing, a child with CP phenotype is found to have a de novo pathogenic variant in KIF1A. The recurrence risk for the parents' next pregnancy is approximately:
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.